Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer.

Abstract excerpt

INTRODUCTION: Neoadjuvant immunotherapy has demonstrated promising efficacy in resectable lung cancer; however, substantial interindividual variability in the treatment response remains. Although programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are established biomarkers of immunotherapy response, the performance of predictive models that integrate these biomarkers remains unclear....

Topics

• Humans
• B7-H1 Antigen
• Lung Neoplasms
• Pathologic Complete Response
• Neoadjuvant Therapy
• Retrospective Studies